BioSpace News Archive

The Nomination Committee of Biotage AB announces its proposal for the election of the Board of Directors and Chairman of the Board for the forthcoming Annual General Meeting.

The shareholders in Biotage AB (publ), Reg. No. 556539-3138, with its registered office in Uppsala kommun, Uppsala län, are hereby summoned to the annual general meeting (the “Meeting”), to be held on Wednesday, April 24, 2019, at 4.00 p.m., at Hotel Radisson Blue in Uppsala, Stationsgatan 4 in Uppsala, Sweden.

Proceeds to build pipeline of novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain

Sobi™ and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders for the 2019 Rare Impact Awards.

Cortexyme, Inc. announced it will convene an educational session at AD/PD™ 2019, the 14th International Conference on Alzheimer’s & Parkinson’s Diseases, which is taking place March 26-31 in Lisbon, Portugal.

Presentations highlight company’s expertise seamlessly integrating human biology, data science and modern chemistry to advance a pipeline of investigational breakthrough precision oncology medicines

Varian today announced it again received the “Best After-Sales Service Award for Radiotherapy Products” in the 2018 Chinese Medical Devices Industry Data and After-Sales Service Survey.

Given the growing challenges of addressing brain illness and injury, One Mind, in collaboration with Janssen Research & Development LLC, Otsuka Pharmaceuticals, Kaiser Permanente, the Gifford Foundation, and Bettina Bryant, is offering up to five Rising Star Research Awards in 2019.

Aimmune Therapeutics, Inc. announced that its phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS, met its primary efficacy endpoint.

The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual meeting